Siliq (brodalumab) / AstraZeneca, Bausch Health, LEO Pharma, Kyowa Kirin - LARVOL DELTA

Epithelial-Derived IL-17C and IL-17E as Psoriatic Inflammation Amplifiers and Targets (AAD 2026) - "Selective IL-17C neutralization (e.g., MOR106) reduces inflammatory markers in preclinical and ex vivo models...IL-17RA blockade (e.g., brodalumab) downregulates IL-17A/F/C/E pathways, normalizing psoriatic gene expression... IL-17C and IL-17E, epithelial-derived cytokines, amplify psoriatic inflammation via autocrine keratinocyte and paracrine Th17/myeloid cell activation, complementing IL-17A/F in psoriatic pathology. Selective IL-17C or IL-17E (via IL-17RB) blockade, with biomarker-guided stratification, offers a rational strategy to advance therapy beyond IL-17A/F and IL-23 targets. Funding: This study was funded by LEO Pharma Ltda."

Immunology • Inflammation • Psoriasis • IL17A • IL17C • IL17RA • IL17RB • IL23A • TNFA

Cost Effectiveness Analysis of Biological Drugs Targeting IL-17 Pathway in Plaque Psoriasis From the Perspective of the Brazilian Private Healthcare System (AAD 2026) - "For PASI 100, the estimated costs were R$160,528 for brodalumab, R$187,807 for bimekizumab, R$252,538 for ixekizumab, and R$335,867 for secukinumab. Immunobiologic therapies are effective and safe for the management of moderate-to-severe psoriasis, with IL-17 inhibitors representing an important treatment class. In this analysis, brodalumab was associated with the most favorable cost-effectiveness profile among IL-17 inhibitors. These findings suggest potential implications for optimizing clinical outcomes and healthcare resource allocation within the Brazilian Supplemental Health System."

Cost effectiveness • HEOR • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • IL17A

Comparative Recapture Rates and Retreatment Efficacy Endpoint Rates Following Biologic Treatment Interruption in Plaque Psoriasis (AAD 2026) - "TNF-α antagonists RR for PASI 75 ranged from 38.1% (infliximab) to 86.5% (certolizumab)...For PASI 90, consistent IL-17 antagonist retreatment showed consistently high REERs (63.4-100%), with brodalumab achieving the highest rates...Newer biologics, particularly IL-17 and IL-23 antagonists, demonstrate superior RRs and REERs compared to those of TNF-α inhibitors. This comparative data can guide treatment selection and inform patient expectations regarding the likelihood of regaining disease control after treatment interruptions, supporting evidence-based clinical decision-making in psoriasis management."

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • IL23A

Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry. (AAD 2026) - " We analyzed crude incidence rates of overall, serious, recurrent, and infections of special interest in patients treated with etanercept, infliximab, certolizumab, adalimumab, ustekinumab, secukinumab, ixekizumab, brodalumab, bimekizumab, guselkumab, risankizumab, tildrakizumab, apremilast, and dimethyl fumarate. Modern systemic therapies for psoriasis show a favorable infection safety profile in real-world settings. IL-17 inhibitors appear to increase the risk of Candida infections, while some biologics may reduce the incidence of respiratory and viral infections."

Clinical • Candidiasis • Dermatology • Human Papillomavirus Infection • Immunology • Infectious Disease • Nephrology • Novel Coronavirus Disease • Psoriasis • Respiratory Diseases • IL17A

Beyond Trial-and-Error: Mechanism-Guided Use of Biologics in Scalp Psoriasis (AAD 2026) - "Ustekinumab offered modest scalp improvement but lacked dedicated trials. IL-17 inhibitors (secukinumab, ixekizumab, brodalumab, bimekizumab) consistently produced the most rapid clearance, with several maintaining high rates of complete response in long-term follow-up. IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) provided excellent durability, with real-world evidence confirming sustained clearance. No scalp-specific outcomes were reported for certolizumab... Biologic selection in scalp psoriasis can move beyond trial-and-error toward mechanism-guided therapy. IL-17 inhibitors are best suited for rapid scalp clearance, while IL-23 inhibitors may optimize long-term durability. These findings support the development of a practical, scalp-specific treatment algorithm to address one of the most visible and burdensome manifestations of psoriasis."

Dermatology • Immunology • Psoriasis • CD8 • IL22 • IL23A

Brodalumab Delivers 8 Years of Safety Success (AAD 2026) - "Pharmacovigilance data throughout 8 years is consistent with a positive safety record, with no completed suicides and a low fungal infection rate."

Clinical • CNS Disorders • Depression • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammatory Bowel Disease • Musculoskeletal Pain • Plaque Psoriasis • Psoriasis • Suicidal Ideation • IL17A • IL17RA

Safety Outcomes of IL-23 Versus IL-17 Inhibitors in Psoriasis: A Multicenter Real-World Study (AAD 2026) - "Adults (≥18 years) with psoriasis initiating an IL-23 inhibitor (guselkumab, risankizumab, tildrakizumab) were compared to those commencing an IL-17 inhibitor (secukinumab, ixekizumab, brodalumab). This first multicenter, real-world head-to-head comparison of IL-23 and IL-17 inhibitors in psoriasis demonstrates a therapeutic trade-off: IL-23 agents reduce infection and mortality risks but increase malignancy and NMSC risks relative to IL-17 inhibitors. These findings offer pivotal evidence to inform individualized, long-term biologic selection in psoriasis, addressing a major gap in dermatologic care."

Clinical • Real-world • Real-world evidence • Dermatology • Genetic Disorders • Herpes Zoster • Immunology • Infectious Disease • Non-melanoma Skin Cancer • Pneumonia • Psoriasis • Respiratory Diseases • Septic Shock • Skin Cancer • Solid Tumor • Varicella Zoster • IL17A • IL23A

Systemic Immune-Inflammation Index (SII) and systemic inflammation response index (SIRI) trend in psoriatic patients treated with brodalumab: a real-life pilot study (AAD 2026) - No abstract available

Clinical • Immunology • Inflammation • Systemic Inflammatory Response Syndrome

IGA NEPHROPATHY FOLLOWING RISANKIZUMAB THERAPY FOR PSORIATIC ARTHRITIS: A CASE REPORT (ISN-WCN 2026) - "He was diagnosed with psoriatic arthritis in 2018 and treated sequentially with brodalumab, adalimumab, and ixekizumab, but these agents failed to adequately control his symptoms. While IgAN has been reported in association with the IL-12/23p40 inhibitor ustekinumab, no previous case of risankizumab-associated IgAN has been described. Further accumulation of biologic-associated IgAN cases, including those involving IL-23p19 inhibition, may help elucidate the underlying disease mechanisms."

Case report • Clinical • Crohn's disease • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • IgA Nephropathy • Immunology • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Renal Disease • Rheumatology • Seronegative Spondyloarthropathies • Ulcerative Colitis • IL12A • IL23A • IL4

BeNeBio: Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (clinicaltrials.gov) - P4 | N=244 | Completed | Sponsor: Radboud University Medical Center | Active, not recruiting ➔ Completed

Head-to-Head • Trial completion • Dermatology • Immunology • Psoriasis • IL17A

Comparing Systemic Therapies for Scalp Psoriasis: A Literature Review (AAD 2026) - "Ixekizumab achieved >90% PSSI improvement across multiple trials, with sustained clearance to 264 weeks; brodalumab showed 94.1% improvement at 52 weeks; secukinumab displayed 95.9% improvement at 52 weeks with durability to 156 weeks. IL-23 inhibitors had lower changes in PSSI scores, with tildrakizumab (34.5→2.9), risankizumab (25→3.2), and guselkumab (17.4→1.3). Ustekinumab (IL-12/23) showed variable results (22–85.6%), with lower scalp clearance by sPGA (52.7% of patients vs. 74% in IL-17A cohort)...Conclusion This review demonstrates higher efficacy of IL-17 inhibitors compared to IL-23/IL-12/23 inhibitors, particularly ixekizumab and brodalumab, for scalp clearance and itch reduction. These findings may guide clinical decision making and highlight the need for consistent endpoint reporting in future trials."

Review • Dermatology • Immunology • Psoriasis • IL12A • IL23A

Biological Treatment of Psoriasis-Data So Far. (PubMed, Pharmaceuticals (Basel)) - "Although topical treatments, systemic treatments (methotrexate, cyclosporine, acitretin), and phototherapy play a role, biologic agents have improved the efficacy of treatment of moderate-to-severe psoriasis. The purpose of this article is to comprehensively review the clinical trial data and evaluate and compare the key features of the currently approved biologic drugs for the treatment of psoriasis."

Journal • Review • Dermatology • Immunology • Inflammation • Psoriasis

Acute Generalized Exanthematous Pustulosis: An Integrated Study of 503 Cases with Emphasis on Drug Culprits, Clinical Features, Diagnosis and Treatment. (PubMed, J Inflamm Res) - "Drugs triggered 94.6% of cases, mainly β-lactam antibiotics (20.7%), non-β-lactam antibiotics (16.3%), and hydroxychloroquine (10.4%)...Systemic corticosteroids were the mainstay (63.8%) of treatment, with cyclosporine (3.7%) and intravenous immunoglobulin (2.5%) used as adjuncts. A few refractory cases received biologics, including IL-17 inhibitors (eg secukinumab, brodalumab) and IL-36 receptor blockade (spesolimab), achieving partial or complete response...We propose a conceptual AGEP causality triage framework integrating latency and allergologic evidence to enhance culprit identification in polypharmacy settings. Given the mechanistic involvement of the IL-36-Th17/IL-17 axis, biologic agents targeting IL-17 or IL-36 pathways show promise in severe or corticosteroid-refractory AGEP, warranting confirmation in larger prospective studies."

Journal • Immunology • Infectious Disease • Pain • IL17A

FIRST-YEAR COST PER RESPONDER FOR BRODALUMAB COMPARED WITH OTHER BIOLOGIC THERAPIES FOR MODERATE TO SEVERE PLAQUE PSORIASIS IN CANADA (ISPOR 2026) - "The treatments (originators and available SEBs) included in this analysis were adalimumab, brodalumab, bimekizumab, etanercept, guselkumab, ixekizumab, risankizumab, secukinumab, and ustekinumab. Tildrakizumab, certolizumab, and infliximab were not part of the selected NMA and were therefore excluded from this analysis... At one year, brodalumab demontrates the greatest cost-effectiveness across PASI 100 and PASI 90 compared with other studied biologic therapies (originators and SEBs), providing optimal value for patients, prescribers, and payers."

Dermatology • Immunology • Psoriasis

Risk of infections in patients with psoriasis treated with biologic agents and new oral small molecules. BIOBADADERM Registry. (PubMed, J Invest Dermatol) - "The overall incidence of serious infections was low across all treatments (5.33%), with infliximab showing the highest incidence rate...Risankizumab and ustekinumab were associated with significantly lower risk of overall infections compared to adalimumab (p < 0.002). The risk of Candida infections was significantly higher with bimekizumab, brodalumab, secukinumab, and ixekizumab. Guselkumab, secukinumab, ixekizumab, and ustekinumab were linked to reduced incidence of respiratory infections. Ixekizumab was associated with a lower risk of COVID-19 infection, whereas dimethyl fumarate showed an increased risk compared with adalimumab. Overall, our findings support the favourable safety profile of biologics and small molecules in psoriasis, particularly regarding serious infections."

Journal • Candidiasis • Dermatology • Immunology • Infectious Disease • Nephrology • Novel Coronavirus Disease • Pneumonia • Psoriasis • Respiratory Diseases

Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study. (PubMed, J Cosmet Dermatol) - "We are the first to provide comparative evidence on the efficacy of newly investigated agents such as deucravacitinib, tildrakizumab, roflumilast and icotrokinra. In general, the IL-17 inhibitors (bimekizumab, ixekizumab, secukinumab, brodalumab) and IL-23 inhibitors (icotrokinra, guselkumab, tildrakizumab) were effective depending upon the outcome and time-point being considered. At 16 weeks, for PSSI-100, ixekizumab 150 mg at weeks 0, 2, 4, 8, and 12 ranked highest; at 16 weeks, for Sc-PGA 0/1 bimekizumab 320 mg every 4 weeks ranked highest; at 8 weeks, for PSSI-100 ixekizumab 80 mg every 2 weeks ranked highest; at 8 weeks, for Sc-PGA 0/1 secukinumab 300 mg at weeks 1, 2, 3 and then every 4 weeks ranked highest. Small-molecule therapies (apremilast, deucravacitinib, roflumilast) improved scalp psoriasis modestly. Our work would guide the design of future studies and clinical decision-making."

Clinical • Journal • Retrospective data • Dermatology • Immunology • Psoriasis • IL17A • IL23A

Drug Survival of Biologics in Bionaive and Bioexperienced Patients With Psoriasis. (PubMed, JAMA Dermatol) - "Adalimumab, secukinumab, and ustekinumab among bionaive patients and adalimumab, bimekizumab, brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, and ustekinumab among bioexperienced patients. In this cohort study in Denmark, among bionaive patients with psoriasis, ustekinumab had superior drug survival compared with adalimumab and secukinumab, and among bioexperienced patients with psoriasis, bimekizumab, guselkumab, and risankizumab had superior drug survival. These results offer insight into the performance of different biologics in the treatment of psoriasis in a routine clinical practice setting."

Journal • Dermatology • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Safety and efficacy of brodalumab for the management of patients with moderate-to-severe psoriasis after 1 year of therapy and its efficacy in obese patients: a single-center real-world clinical practice study. (PubMed, Actas Dermosifiliogr) - No abstract available

Journal • Real-world evidence • Dermatology • Immunology • Obesity • Psoriasis

The Relative Efficacy of Monotherapies for Palmoplantar Pustulosis and Palmoplantar Psoriasis: A Network Meta-Analysis Study of the Palmoplantar Spectrum. (PubMed, Medicina (Kaunas)) - " Twenty trials (n = 2030) with 23 active comparators provided data for 10 endpoints (fresh pustules at 4 weeks; PPPASI-50/75 and mean percentage and absolute PPPASI change at 12 and 16 weeks). The NMA indicates efficacy of ixekizumab and brodalumab (IL-17 inhibitors), guselkumab (IL-23 inhibitor), and spesolimab (IL-36 inhibitor) in managing palmoplantar pustulosis."

Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • Pustular Psoriasis • IL17A • IL23A

Behçet's disease occurred after brodalumab initiation in a patient with chronic non-bacterial osteitis: a case-based literature review. (PubMed, Rheumatol Int) - No abstract available

Journal • Review • Immunology • Rare Diseases

Biologics-induced cutaneous pseudolymphomas: a narrative review with an illustrative case of brodalumab-induced pseudolymphoma. (PubMed, Drugs Context) - "We provide a concise narrative review of biologics-induced CPLs and illustrate the topic with the first reported case of brodalumab-induced pseudolymphoma in a patient with psoriasis. Understanding this rare adverse event is crucial for early recognition, correct histopathological interpretation and appropriate management."

Journal • Review • Dermatology • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Oncology • Psoriasis

Microneedle-based delivery of cell membrane vesicles as IL-17RA decoys for Psoriasis treatment. (PubMed, J Nanobiotechnology) - "Brodalumab, the only approved IL-17RA-blocking antibody, suggests robust clinical efficacy...In an imiquimod (IMQ)-induced murine psoriasis model, the topical application of mIL-17RA-CMVs-MNs significantly alleviated disease severity, as evidenced by a remarkable reduction in Psoriasis Area and Severity Index (PASI) scores, suppression of epidermal hyperplasia, and normalization of spleen index...This study presents a pioneering approach that synergizes the broad-spectrum neutralization capability of engineered decoy receptor vesicles with the localized and minimally invasive delivery advantage of microneedles. These findings position IL-17RA-CMVs (or IL-17RA-CMVs-MNs) as a highly promising and translatable therapeutic modality for the treatment of psoriasis and potentially other IL-17-mediated inflammatory diseases."

Journal • Dermatology • Immunology • Inflammation • Psoriasis • Psychiatry • Suicidal Ideation • CCL20 • CXCL1 • IL17A • IL17RA

Brodalumab's 8-Year Journey in Plaque Psoriasis: Insights into Efficacy, Safety, and Real-World Evidence. (PubMed, J Drugs Dermatol) - "These findings reinforce that brodalumab is an important, well-tolerated therapeutic option for achieving high levels of disease control in patients with moderate-to-severe psoriasis, including those with prior biologic exposure or difficult-to-treat disease manifestations. &nbsp."

HEOR • Journal • Real-world evidence • Dermatology • Immunology • Oncology • Psoriasis • Psychiatry • Suicidal Ideation • IL17A • IL17RA

Intestinal homeostasis alteration toward mucosal inflammation with blocking IL-17 in psoriasis patients: a case series. (PubMed, Transl Gastroenterol Hepatol) - "The median age was 64 years, the disease duration was 31 years, two were female, four received secukinumab, and one received brodalumab. Proteobacteria was increased after the administration. Although no one occurred clinical symptoms after IL-17 inhibition in this case series, blocking IL-17 signals altered intestinal homeostasis toward mucosal inflammation."

Journal • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Mucositis • Psoriasis • IL17A

Real-World Evidence of Brodalumab Effectiveness for the Treatment of Psoriasis. (PubMed, J Drugs Dermatol) - "The evidence collectively establishes brodalumab as a valuable therapeutic option, particularly for patients with treatment-resistant psoriasis and challenging subtypes. &nbsp."

HEOR • Journal • Real-world evidence • Review • Dermatology • Dermatopathology • Immunology • Psoriasis • Pustular Psoriasis • IL17A